ATL. Issue 8 (1st October 2018)

• Record Type: Journal Article
• Authors: Gorodnova, Tatyana V.; Kotiv, Khristina B.; Ivantsov, Alexandr O.; Mikheyeva, Olga N.; Mikhailiuk, Galina I.; Lisyanskaya, Alla S.; Mikaya, Nikolay A.; Guseynov, Konstantin D.; Bondarev, Nikolay E.; Matveyeva, Nataliya S.; Nekrasova, Ekatherina A.; Sidoruk, Anna A.; Roman, Laslo D.; Manikhas, Georgiy M.; Belyaev, Alexey M.; Sokolenko, Anna P.; Berlev, Igor V.; Imyanitov, Evgeny N.
• Is Part Of: International journal of gynecological cancer. Volume 28:Issue 8(2018)
• Page Start: 1498
• Page End: 1506
• Publication Date: 2018-10-01
• Subjects: BRCA1 -- Mitomycin C -- Mutation -- Neoadjuvant therapy -- Ovarian cancer -- Clinical trial; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0000000000001352
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: Cisplatin and mitomycin C exert high activity towards BRCA1-deficient cells. This study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1 -associated ovarian cancer (OC). Methods: Twelve OC patients, who could not be treated by primary debulking surgery owing to extensive tumor spread, were given neoadjuvant cisplatin (100 mg/m 2 ) and mitomycin C (10 mg/m 2 ) every 4 weeks for 3 (n = 9), 2 (n = 2), or 4 (n = 1) cycles. Results: The decrease of tumor burden and complete surgical cytoreduction were achieved in all patients. Pathologic complete response, defined as the absence of tumor cells in surgically removed tissues, was observed in 2 (17%) of 12 cases. Retrospective analysis of 62 OC in BRCA1 mutation carriers subjected to conventional neoadjuvant chemotherapy schemes revealed 36 objective tumor responses (58%) and 37 instances (60%) of complete cytoreductive surgery; however, none of these patients demonstrated pathologic complete response. Conclusions: The combination of cisplatin plus mitomycin C showed promising results in BRCA1-driven OC and therefore deserves further clinical evaluation.